Class-Wide REMS: "A Self-Propagating Purgatory"

It hasn't been easy for two dozen companies to work together in trying to craft a viable class-wide risk management program for long-acting opioids. If they are successful, expect FDA to push for more class-wide REMS.

By Laura Helbling

The opioid class-wide Risk Evaluation & Mitigation Strategy poses an unprecedented challenge for industry cooperation among competitors. And, if it...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Agency Leadership

More from Pink Sheet